It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Melanoma cells rely on developmental programs during tumor initiation and progression. Here we show that the embryonic stem cell (ESC) factor Sall4 is re-expressed in the Tyr::NrasQ61K; Cdkn2a−/− melanoma model and that its expression is necessary for primary melanoma formation. Surprisingly, while Sall4 loss prevents tumor formation, it promotes micrometastases to distant organs in this melanoma-prone mouse model. Transcriptional profiling and in vitro assays using human melanoma cells demonstrate that SALL4 loss induces a phenotype switch and the acquisition of an invasive phenotype. We show that SALL4 negatively regulates invasiveness through interaction with the histone deacetylase (HDAC) 2 and direct co-binding to a set of invasiveness genes. Consequently, SALL4 knock down, as well as HDAC inhibition, promote the expression of an invasive signature, while inhibition of histone acetylation partially reverts the invasiveness program induced by SALL4 loss. Thus, SALL4 appears to regulate phenotype switching in melanoma through an HDAC2-mediated mechanism.
Melanoma cells can switch between proliferative and invasive phenotypes. Here the authors show that the embryonic stem cell factor Sall4 is a negative regulator of melanoma phenotype switching where its loss leads to the acquisition of an invasive phenotype, due to derepression of invasiveness genes.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details











1 University of Zürich, Institute of Anatomy, Zürich, Switzerland (GRID:grid.7400.3) (ISNI:0000 0004 1937 0650)
2 University of Zürich, Institute of Anatomy, Zürich, Switzerland (GRID:grid.7400.3) (ISNI:0000 0004 1937 0650); Memorial Sloan Kettering Cancer Center, Developmental Biology, The Center for Stem Cell Biology, New York, USA (GRID:grid.51462.34) (ISNI:0000 0001 2171 9952)
3 Linköping University, Wallenberg Centre for Molecular Medicine, Linköping, Sweden (GRID:grid.5640.7) (ISNI:0000 0001 2162 9922); Linköping University, Department of Biomedical and Clinical Sciences, Division of Molecular Medicine and Virology; Faculty of Medicine and Health Sciences, Linköping, Sweden (GRID:grid.5640.7) (ISNI:0000 0001 2162 9922)
4 University of Zürich, Department of Molecular Mechanisms of Disease, Zürich, Switzerland (GRID:grid.7400.3) (ISNI:0000 0004 1937 0650)
5 University Hospital of Zürich, Department of Dermatology, Zürich, Switzerland (GRID:grid.412004.3) (ISNI:0000 0004 0478 9977)
6 Max-Delbrück-Center for Molecular Medicine, Berlin, Germany (GRID:grid.419491.0) (ISNI:0000 0001 1014 0849); Charité-Universitätsmedizin Berlin, Berlin, Germany (GRID:grid.6363.0) (ISNI:0000 0001 2218 4662)
7 Memorial Sloan Kettering Cancer Center, Developmental Biology, The Center for Stem Cell Biology, New York, USA (GRID:grid.51462.34) (ISNI:0000 0001 2171 9952)
8 University of Zürich, Institute of Molecular Life Sciences, Zürich, Switzerland (GRID:grid.7400.3) (ISNI:0000 0004 1937 0650)
9 Linköping University, Wallenberg Centre for Molecular Medicine, Linköping, Sweden (GRID:grid.5640.7) (ISNI:0000 0001 2162 9922); Linköping University, Department of Biomedical and Clinical Sciences, Division of Molecular Medicine and Virology; Faculty of Medicine and Health Sciences, Linköping, Sweden (GRID:grid.5640.7) (ISNI:0000 0001 2162 9922); University of Zürich, Institute of Molecular Life Sciences, Zürich, Switzerland (GRID:grid.7400.3) (ISNI:0000 0004 1937 0650)